PharmaVOICE: CEO Dave Johnson named one of the 100 Most Inspiring People

,

Big Picture, Big Rewards – David Johnson, Ph.D., locks up his bicycle after a harrowing ride navigating hills and traffic to make his way to South San Francisco, Calif., the birthplace of biotechnology. It’s how he gets to and from work at GigaGen, a company he founded in 2010 to translate his research in single cell genomics into novel therapies for patients in need.

Read the full story.

GigaGen Announces Issuance of US Patent for Functional Analysis Methods in the Discovery and Development of Therapeutic Antibodies

,

GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced the United States Patent and Trademark Office has issued U.S. Patent No. 10,329,557, covering methods that enable parallel functional analysis of single cells, a core capability of the company’s Surge™ technology. With its massively parallel single-cell bioassay platform, GigaGen can interrogate complex mixtures of cells in search of promising drug targets and therapeutic candidates.

Read the full press release.

BioSpace: 6 Award-Winning Life Science Companies in the Bay Area

,

There are numerous ways to rank a company as “the best place to work.” Some listings rank companies by pay, others by how “happy and engaged” the workforce is, others by culture and benefits. Some rankings use metrics while others are based on employee surveys. Here’s a look at six San Francisco Bay Area life science companies that have hit a variety of “best of” lists recently, in no particular order.

GigaGen. Based in South San Francisco, GigaGen is a small biotech company working to advance a pipeline of immunotherapies for cancer and immune deficiencies. The company’s tech platform, dubbed Surge technology, leverages microfluidics, genomics and protein library engineering to improve target selection, candidate identification and preclinical efficacy assessment. The company recently published an article in the journal mAbs showing the feasibility and benefit of its Surge antibody discovery and engineering platform for rapid monoclonal antibody discovery. GigaGen was recently ranked as one of the “Best Places to Work in the Bay Area” by the San Francisco Business Journal.

Read the full story.

GigaGen Publishes Study in Peer-Reviewed Journal mAbs, Validating Feasibility and Benefit of Rapid Parallel Immunization Protocols for Discovery of Novel Monoclonal Antibodies

,

GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced the publication of a study that shows the feasibility and benefit of its Surge™ antibody discovery and engineering platform for rapid monoclonal antibody discovery using multiple immunization protocols in parallel. The study has been published online in the peer-reviewed scientific journal mAbs, and it will be available as the cover article in the upcoming July printed issue.

Read the full press release.

STAT: GigaGen CEO Dave Johnson, PhD, discusses why biotech execs need to create an environment that fosters a truly scientific culture

,

“What traditions do you want to follow for your baby?” asked the midwife leading our prenatal education group.

As we went around the circle of parents-to-be, most couples discussed holiday traditions, camping trips, and weekend routines. When it was my turn to share, I thought about the pseudoscience that had been espoused in this group — the alleged benefits of eating the placenta, theories about the harmful effects of vaccines, and the like.

“I want a facts-based, scientific household,” I said. “For example, is breastfeeding better than formula? To me the only thing that matters is the clear scientific consensus that breastfed infants grow up to be, on average, advantaged in some way — maybe healthier or smarter.”

Read the full story.

GigaGen CEO David Johnson to Present on Surge Technology at 2019 Antibody Engineering & Therapeutics Asia Meeting

,

GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced that David Johnson, Ph.D., chief executive officer, will present at the 2019 Antibody Engineering & Therapeutics Asia Meeting. Dr. Johnson will also co-chair the presentation, which will take place at 8:45 a.m. JST on February 26, 2019, at the Hilton Tokyo Bay Hotel in Tokyo, Japan.

Read the full press release.

GigaGen Publishes Study Demonstrating Optimal Method for Selecting OX40 Therapeutic Candidates from Antibody Repertoires

,

GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced the publication of a study showing how it adapted its Surge™ antibody discovery and engineering platform to improve selection of OX40 agonists. The study has been published online in the peer-reviewed scientific journal, Antibodies, as part of the special issue Antibody Repertoire Mining for Immune Profiling, Antibody Discovery and Vaccine Design.

Read the full press release.

GigaGen Promotes Adam Adler, Ph.D., to Chief Scientific Officer

,

GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced the promotion of Adam Adler, Ph.D., to Chief Scientific Officer (CSO). Previously, Dr. Adler was the company’s Vice President of Research and Development. In addition, Gigagen has promoted Rena Mizrahi, Ph.D to Vice President of Process Development and Catherine Medina to Vice President of Operations.

Read the full press release.

GigaGen Announces Appointment of Erica Stone, Ph.D., as Director, Immuno-Oncology

,

GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced that Erica Stone, Ph.D., has joined the company as director, immuno-oncology.

“We welcome award-winning immunologist Dr. Stone to the GigaGen team,” said Dave Johnson, Ph.D., CEO of GigaGen. “Dr. Stone brings with her a deep understanding of the tumor microenvironment and checkpoint inhibitors that is perfectly paired with our novel antibody discovery and engineering platform, Surge. Surge enables us to uncover new antibodies that have historically been missed by traditional discovery methods such as hybridoma, and with Dr. Stone’s expertise we look forward to identifying immuno-oncology drug candidates with the greatest potential to improve patient treatment.”

Read the full press release.

 

GigaGen CEO David Johnson to Present at 2018 Antibody Engineering & Therapeutics Meeting

,

GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced that David Johnson, Ph.D., chief executive officer, will present at the 2018 Antibody Engineering & Therapeutics Meeting. Dr. Johnson’s presentation will take place at 3:15 p.m. PST on December 9, 2018, at the Manchester Grand Hyatt in San Diego, Calif.

Read the full press release.